Document:

Exhibit 10.24

                                SUPPLY AGREEMENT

                                 by and between

                                 AstraZeneca AB

                                       and

                                 INyX Pharma Ltd

                               DATE: 11 June 2004

<PAGE>

                                TABLE OF CONTENTS

1.    Definitions..............................................................1
2.    Construction.............................................................4
3.    Amendment................................................................4
4.    Supply of Products.......................................................4
5.    Forecasting..............................................................4
6.    Orders...................................................................5
7.    Delivery and Title.......................................................5
8.    Delay in Delivery........................................................6
9.    Price....................................................................6
10.   Invoicing and Pavment....................................................6
11.   Continuous Improvements..................................................7
12.   Shortfalls, Damages & Defects............................................7
13.   Quality, Manufacturing and Storage.......................................8
14.   Product Recall...........................................................8
15.   Responsibilities For Scrapped/Wasted Materials...........................9
16.   Printed Packaging and Artwork............................................9
17.   Ownership and Use........................................................9
18.   Legal and Regulatory Requirements.......................................10
19.   Corporate Responsibility................................................10
20.   Additional Representations and Warranties...............................10
21.   Force Majeure...........................................................11
22.   Term and Termination....................................................12
23.   Tech Transfer to AstraZeneca or a Second Supplier.......................14
24.   Most Favoured Customer..................................................15
25.   Confidentiality.........................................................15
26.   Improvements............................................................16
27.   Insurance...............................................................16
28.   Use of Name.............................................................17
29.   Notices.................................................................17
30.   Relationship of the Parties.............................................17
31.   Assignment..............................................................17
32.   Expenses................................................................18
33.   Waiver and Non-Exclusion of Remedies....................................18
34.   Severability............................................................18
35.   Governing Law and Disputes..............................................18
36.   Counterparts............................................................19
37.   Execution...............................................................19

EXHIBIT 1 Product, Product Requirements and Price
EXHIBIT 2 Logistic Arrangement
EXHIBIT 3 Contact People
EXHIBIT 4 Quality Assurance Agreement
EXHIBIT 5 AstraZeneca Property
EXHIBIT 6 General Work Flow For The Artwork Process

                                       i
<PAGE>

                                SUPPLY AGREEMENT

This Supply  Agreement  (the  "Agreement")  is made on 11 June 2004  ("Effective
Date") by and between

(1)      AstraZeneca AB, a company  incorporated in Sweden under no. 556011-7482
         with offices at S-151 85 Sodertdlje, Sweden ("AstraZeneca"); and

(2)      INyX Pharma Ltd, a company incorporated in the United Kingdom under no.
         4573515 with offices at 6 Seymour Court, Manor Park, Runcorn, Cheshire,
         UK, WA7 1SY ("Inyx")

Recitals
--------

         (A)      WHEREAS,  AstraZeneca  intends to outsource the manufacturing,
                  testing and release of Product (as defined herein).

         (B)      WHEREAS, Inyx has the ability and desire to manufacture,  test
                  release and supply the Product.

         (C)      WHEREAS,  the Parties have agreed to enter into this Agreement
                  to set forth the  general  terms and  conditions  on which the
                  supply and  additional  service of the Product will be carried
                  out.

Agreement
---------

NOW,  THEREFORE,  in  consideration  of the mutual  covenants  contained in this
Agreement,   and  other  good  and  valuable  consideration,   the  receipt  and
sufficiency  of which are hereby  acknowledged,  the  Parties,  intending  to be
legally bound, agree as follows:

1.       Definitions
         -----------

Unless otherwise  specifically  provided in this Agreement,  the following terms
shall have the following meanings:

1.1      "Affiliates" means, with respect to a Person, any Person that controls,
         is controlled by or is under common control with such first Person. For
         purposes  of this  definition  only,  "control"  means (a) to  possess,
         directly or indirectly,  the power to direct the management or policies
         of a  Person,  whether  through  ownership  of  voting  securities,  by
         contract   relating  to  voting  rights  or  corporate   governance  or
         otherwise,  or (b) to own, directly or indirectly,  fifty percent (50%)
         or  more  of the  outstanding  voting  securities  or  other  ownership
         interest of such Person.

1.2      "Applicable Laws and Regulations" with respect to the Product,  has the
         meaning  defined in the  Quality  Assurance  Agreement  and the Product
         Requirements.

1.3      "AstraZeneca Information" means all confidential data and information
         related to or comprised in Intellectual Property Rights and Know-How,
         as well as other information in relation to AstraZeneca's general
         business operations, the Product or its manufacture, which is owned by
         AstraZeneca or which is in its possession and which AstraZeneca is
         entitled to disclose.

<PAGE>

1.4      "AstraZeneca Property" means the property owned by AstraZeneca at Inyx'
         facilities set out in Exhibit 5, AstraZeneca Property.

1.5      "Change  of  Control"  with  respect to any  Person,  means an event in
         which:

         (a)      any other  Person or group of Persons,  except  Affiliates  of
                  Inyx,  acquires  beneficial  ownership of  securities  of such
                  first Person representing more than fifty percent (50%) of the
                  voting power of the then outstanding  securities of such first
                  Person with respect to the election of directors of such first
                  Person; or

         (b)      such  Person  enters into a merger,  consolidation  or similar
                  transaction  with another Person in which such first Person is
                  not the surviving entity in such transaction.

1.6      "Confidential  Information"  means all  AstraZeneca  Information or all
         Inyx Information, as the context may require, disclosed by or on behalf
         of the relevant  Party to the other Party pursuant to this Agreement in
         written, oral or any other form.

1.7      "Disclosing Party" means the Party disclosing Confidential Information.

1.8      "Price  Review Date" means the date on which the then current Price for
         a Product will be reviewed as specified in Exhibit 1.

1.9      "Fixed  Price Term" means a term for which the Price will remain  fixed
         as specified in Exhibit 1.

1.10     "Force  Majeure  Party"  means  a Party  prevented  or  delayed  in its
         performance under this Agreement by an event of Force Majeure.

1.11     "Force Majeure" has the meaning defined in the Force Majeure Section.

1.12     "Forecast" has the meaning set forth in Section 5.1.

1.13     "Improvement" means any invention, discovery, upgrading or modification
         and all other Intellectual Property Rights (whether patentable or not);
         for the Product it shall  include  any new  indication,  dosage  forms,
         formulations or delivery systems.

1.14     "Intellectual  Property  Rights"  means  confidential  know-how,  trade
         secrets, patent rights, trade marks, service marks, trade names, design
         rights,  copyright  (including  rights in  computer  software)  and any
         rights or property  similar to any of the  foregoing in any part of the
         world,  whether registered or not, together with the right to apply for
         the  registration  of any  such  rights,  and all  rights  or  forms of
         protection  having  equivalent  or similar  effect,  in any part of the
         world.

1.15     "Invoice  Currency"  means the  currency in which the  Product  will be
         invoiced and paid.

                                       2
<PAGE>

1.16     "Inyx Information" means all confidential data and information  related
         to or comprised in Intellectual  Property Rights and know-how,  as well
         as other information in relation to Inyx's general business  operations
         and manufacturing processes,  which is owned by Inyx or which is in its
         possession and which it is entitled to disclose.

1.17     "Know-How" means (i) all technical  information or data relating to the
         Products,  whether  protected by  Intellectual  Property Rights or not,
         including  but not limited to  technology,  processes,  specifications,
         formulas,  procedures,  techniques,  practices and instructions of, and
         scientific,   analytical  and  technical  data  and  studies  for,  the
         synthesis,   manufacturing,   pharmaceutical  processing,  formulation,
         packaging,  labeling storage and  transportation  of the Products;  and
         (ii)  non-clinical  and  clinical  data  and  studies  relating  to the
         Products.

1.18     "Lead-Time" means the time from AstraZeneca placing of a purchase order
         or a notification requesting delivery under a frame purchase order, as
         the case may be, until delivery of Products.

1.19     "Manufacturing  Process"  means any  process  (or step in any  process,
         including  packaging,  quality  control and quality  assurance) used or
         planned  to be used by Inyx  (or  any of its  permitted  Affiliates  or
         subcontractors) for manufacturing the Product.

1.20     "Parties"   means   AstraZeneca  and  Inyx  and  "Party"  means  either
         AstraZeneca or Inyx, as the context requires.

1.21     "Person" means an individual, sole proprietorship, partnership, limited
         partnership,   limited  liability  partnership,   corporation,  limited
         liability  company,   business  trust,  joint  stock  company,   trust,
         incorporated   association,   joint   venture  or  similar   entity  or
         organization,   including  a  government   or  political   subdivision,
         department or agency of a government.

1.22     "Price" means the amount payable from time to time for such Product, as
         determined in accordance with the terms hereof.

1.23     "Product"  means the finished  product to be supplied  pursuant to this
         Agreement.

1.24     "Product  Requirements"  means the  specifications and requirements for
         the Product as  specified  in an appendix to the QAA and referred to in
         Exhibit 1 of this  Agreement  as the same may be  updated  from time to
         time in accordance with the QAA and the regulatory approved artwork.

1.25     "Product  Item"  means  the  smallest  unit  of  Products  that  can be
         purchased by  AstraZeneca  or its  Affiliates and identified by an item
         number.

1.26     "Quality  Assurance  Agreement"  or "QAA" means the  quality  assurance
         agreement  entered  into by the  Parties,  a copy of which is  attached
         hereto as Exhibit 4, as the same shall be amended from time to time

1.27     "Receiving Party" means the Party to whom  Confidential  Information is
         disclosed.

                                       3
<PAGE>

1.28     "Term" means the period  beginning on the Effective Date and continuing
         until the date upon which this  Agreement is  terminated  in accordance
         with Article 22.

2.       Construction
         ------------

2.1      Except where the context requires otherwise, whenever used the singular
         includes the plural,  the plural includes the singular,  the use of any
         gender is applicable to all genders and the word "or" has the inclusive
         meaning  represented  by the  phrase  "and/or".  The  headings  of this
         Agreement are for convenience of reference  only. The term  "including"
         or  "includes"  as used  in this  Agreement  means  including,  without
         limiting the  generality of any  description  preceding  such term. The
         wording of this  Agreement  shall be deemed to be the wording  mutually
         chosen  by the  Parties  and no rule of  strict  construction  shall be
         applied against any Party.

2.2      The  Exhibits (as amended from time to time by agreement of the Parties
         in  writing)  form part of this  Agreement  and have the same force and
         effect  as if  expressly  set  out in the  body of the  Agreement.  Any
         reference to the  Agreement  includes the  Exhibits.  Any breach of the
         Exhibits shall be deemed a breach of this Agreement.

2.3      Save for as set out in  Section  13.1,  if  there is any  inconsistency
         between the Exhibits and this  Agreement,  the terms and  conditions of
         this Agreement shall govern and any inconsistency between the Exhibits,
         the Exhibits will take precedence in the order they appear.

3.       Amendment

3.1      Any amendment or  modification of this Agreement must be in writing and
         signed by authorized representatives of both Parties.

4.       Supply of Products

4.1      Inyx  agrees to  manufacture,  package,  test,  release and deliver and
         manage stock for the Products under this Supply  Agreement  exclusively
         for AstraZeneca or its Affiliates.

4.2      In addition,  Inyx shall perform post  marketing  stability  tests to a
         mutually agreed cost and format.

5.       Forecasting
         -----------

5.1      Forecast:  AstraZeneca  shall each calendar quarter provide Inyx with a
         non-binding forecast for AstraZeneca and its Affiliates requirements of
         Products  during the following  twelve (12) month period  ("Forecast").
         The Forecast submitted in October each year shall however cover fifteen
         (15) months.

5.2      Inyx shall without delay notify  AstraZeneca  if Inyx does not have the
         capacity to deliver Products in accordance with the Forecast.

                                       4
<PAGE>

6.       Orders
         ------

6.1      Purchase order:  AstraZeneca shall place a firm purchase order for each
         requested Product to Inyx with a Lead-Time of twenty six (26) weeks.

6.2      AstraZeneca  may at its option place frame  purchase  order for one (1)
         year of  supply  of  Products  and  will in such  case  notify  Inyx on
         requested  delivery  dates.  The Lead-Time will in such case be sixteen
         (16) weeks from such notification.

6.3      Order  confirmation:  Inyx shall  confirm the  purchase  orders and the
         delivery  date  within two (2) weeks from the  receipt of the  purchase
         order.

6.4      Time is of essence to this Agreement.

6.5      The delivery  performance as to mutually agreed measurement criteria is
         to be followed up by Inyx each month and  reported  to  AstraZeneca  as
         inputs to the Operation Planning Meetings (see below).

6.6      Communication:   Any  deviation   from  the  delivery  plan  is  to  be
         communicated  to  AstraZeneca  as soon as  possible  in order to enable
         AstraZeneca to take necessary  action to minimize any negative  effects
         in the market.

6.7      Communication on market changes:  AstraZeneca  shall inform Inyx of any
         major changes in the market or other information, which may have impact
         on sales and therefore the supply of Products under this Agreement.

6.8      Operation  Planning  Meetings shall be held quarterly  unless otherwise
         agreed  upon  between  the  Parties.  The agenda  shall  comprise:  (a)
         performance report; (b) market intelligence; (c) supply capability; (d)
         possible  capacity problems and  prioritisations;  (e) forward planning
         including  changes,   withdrawals.   AstraZeneca  shall  initiate  such
         meetings.

7.       Delivery and Title
         ------------------

7.1      Inyx shall deliver and supply each Product  ordered by  AstraZeneca  in
         accordance with the term Ex Works Runcorn (Incoterms 2000).

7.2      The risk and  title to the  Products  shall  pass to  AstraZeneca  upon
         delivery according to the delivery Incoterm in Section 7.1.

7.3      In the event of a delay by  AstraZeneca  to collect the Products,  Inyx
         shall have responsibility for ensuring that the Products are stored and
         maintained in accordance  with the QAA until  AstraZeneca has collected
         such Products.  AstraZeneca  shall remunerate Inyx for any direct costs
         associated by AstraZeneca's delay to collect Products.

                                       5
<PAGE>

8.       Delay in Delivery
         -----------------

8.1      In the event that Inyx  discovers that the delivery date cannot be met,
         Inyx shall immediately  notify AstraZeneca in writing stating the cause
         of the delay and present a revised  date for  delivery or schedule  for
         delayed deliveries.  Inyx shall use commercially best efforts to reduce
         such delay.  Inyx shall notify  AstraZeneca  of any delay of the day of
         dispatching within five working days.

         8.1.1    In case of a delay  of  delivery,  which  is due to Inyx or to
                  circumstances   for  which  Inyx  is   directly   responsible,
                  AstraZeneca is entitled to liquidated damages.  The liquidated
                  damages  shall be payable at a rate of one percent (1%) of the
                  Price of the  Products  in delay  (the  Price in the  relevant
                  purchase order) per completed week of delay up to a maximum of
                  eight percent (8%) of such Price.

         8.1.2    Claims by AstraZeneca for liquidated damages shall not operate
                  a waiver of any  rights to  cancel a delayed  delivery  or any
                  other rights under this Agreement.

8.2      Inyx is  responsible  for any  delay in  transportation  or in  customs
         control  due  to  deficiencies  in  the  documentation  supporting  the
         delivery of Products delivered under this Agreement.

9.       Price
         -----

9.1      The  Price of the  Product  is  specified  in  Exhibit  1. The Price is
         exclusive  of Value Added Tax,  which,  if payable,  shall be borne and
         paid by AstraZeneca against the provision by Inyx of an appropriate VAT
         invoice.

9.2      The Price at the time of signing  will remain fixed for the Fixed Price
         Term.  On the Price Review Date and on each  anniversary  of such Price
         Review  Date,  the Parties will adjust the Price after  agreement.  The
         Parties shall in such review take into account price review  parameters
         set out in Exhibit 1.

9.3      If  the  Parties  fail  to  agree  on a  revised  Price  prior  to  the
         commencement  of the new Fixed Price Term,  then the Price shall be set
         according to the price review formula set out in Exhibit 1.

10.      Invoicing and Payment
         ---------------------

10.1     Inyx shall issue an invoice to AstraZeneca for the applicable Price for
         all Products  delivered to  AstraZeneca.  The invoice  shall  contain a
         reference  identifying the AstraZeneca's  purchase order as well as the
         relevant AstraZeneca Product article number identifying the Product.

10.2     AstraZeneca shall pay all invoices in full within thirty (30) days from
         receipt of the  relevant  invoice and  certificates  for the  Products,
         whichever  is  later,  to Inyx as  detailed  in  Exhibit  2 or  Product
         Requirements;  provided,  however,  that  if  AstraZeneca  rejects  any
         Products  pursuant to Section  12.1,  then payment  shall be due within
         thirty (30) days of 11 June 2004 receipt by  AstraZeneca  of (i) notice
         from the  independent  expert (as  described in Section  12.4) that the

                                       6
<PAGE>

         Products are conforming or (ii)  conforming  Products in replacement of
         any  Non-Conforming  Products (as defined herein) or otherwise,  as the
         case may be.

11.      Continuous Improvements
         -----------------------

11.1     Inyx  shall  continuously  use  its  best  commercial  efforts  to make
         improvements  in purchasing  prices of raw material and other materials
         as well as in its Manufacturing Process of Product in order to decrease
         the Price.  After Inyx'  recovery of its expenses or  write-offs of any
         investment  made, any cost reduction shall be split between the parties
         on a 50/50 basis.

11.2     Any  changes  in  the  Manufacturing  Process  with  an  impact  on the
         Chemistry,  Manufacturing and Control documentation shall be subject to
         AstraZeneca's  prior written approval and change control system set out
         in the Quality Assurance Agreement.

12.      Shortfalls, Damages & Defects
         -----------------------------

12.1     If any  shipment  of Product  delivered  by Inyx  contains  any damage,
         shortage or defect of the  Product,  AstraZeneca  shall notify Inyx (a)
         within  sixty  (60) days of receipt of such  shipment  if such  damage,
         shortage or defect can be  ascertained  by the  exercise of  reasonable
         diligence upon  examination by AstraZeneca on receipt of such shipment,
         or (b)  within  sixty  (60) days  after  discovery  of the same if such
         damage,  shortage or defect  cannot be  ascertained  by the exercise of
         reasonable diligence upon examination by AstraZeneca on receipt of such
         shipment (including non-conformities relating to stability).

12.2     If there is any defect in or damage to any Product delivered by Inyx or
         documentation  (collectively,  "Non-Conforming Product"), Inyx shall at
         AstraZeneca's option without any undue delay either:

         12.2.1   replace the Non-Conforming Product with conforming Product, at
                  Inyx's expense; or

         12.2.2   refund to AstraZeneca the cost paid to Inyx by AstraZeneca for
                  such Non-Conforming  Product,  or, if the invoice has not been
                  paid, cancel the invoice; and

         12.2.3   in either case,  compensate  AstraZeneca  for any direct costs
                  incurred as a result of the delivery of Non-Conforming Product
                  and costs for removal or disposal of Non-Conforming Product.

12.3     If there is any  shortfall  in any  shipment of Product  delivered,  as
         against  the  relevant  order  placed  by  AstraZeneca,  Inyx  shall at
         AstraZeneca's option without any undue delay either:

         12.3.1   deliver the  quantity of shorted  Product to  AstraZeneca,  at
                  Inyx's cost; or

                                       7
<PAGE>

         12.3.2   credit or refund AstraZeneca, at AstraZeneca's discretion, for
                  the amount of shortfall; and

         12.3.3   in either case,  compensate  AstraZeneca  for any direct costs
                  incurred as a result of such shortfall.

12.4     If a dispute  arises  between the  Parties as to any claimed  damage or
         defect in the Product or shortage of Products  delivered,  which cannot
         be  resolved by the  Parties  within  thirty (30) days of a claim being
         notified by  AstraZeneca  to Inyx,  either  Party may require  that the
         matter in dispute be  referred  to an  independent  expert  (such as an
         independent  testing  laboratory)  selected by agreement of the Parties
         or, failing agreement,  appointed by the Stockholm Chamber of Commerce,
         at the  instigation  of either Party.  Such referral will be solely for
         the  purpose  of  establishing  whether  or not there is any  shortage,
         damage or defect (as the case may be) in the Product  delivered by Inyx
         to  AstraZeneca.  Except in the case of fraud or manifest  error on the
         part of such  independent  expert,  the  decision  of such  independent
         expert will be binding  upon the  Parties.  If the  independent  expert
         decides  there was no  shortage,  damage or  defect in the  Product  in
         question,  the  costs  of the  independent  expert  will  be  borne  by
         AstraZeneca.  In all other circumstances,  the costs of the independent
         expert will be borne by Inyx.

12.5     The  remedies  set forth in this Article 12 shall be in addition to any
         other rights that  AstraZeneca  or Inyx may have hereunder or at law as
         specified in this Agreement.

13.      Quality, Manufacturing and Storage
         ----------------------------------

13.1     In manufacturing, testing, storing, releasing and delivering (according
         to the agreed Incoterm) Product to AstraZeneca,  Inyx shall comply with
         all  of the  provisions  and  requirements  of  the  Quality  Assurance
         Agreement  and the  Product  Requirements.  Any  breach of the  Quality
         Assurance  Agreement  or the  Product  Requirements  shall be  deemed a
         breach of this  Agreement  as set out in Section  2.2 In the event of a
         discrepancy between the Quality Assurance Agreement and this Agreement,
         the terms of the Quality Assurance Agreement shall control.

13.2     Inyx and  AstraZeneca  agree to cooperate in  attempting to resolve all
         product  quality  complaints  as  set  out  in  the  Quality  Assurance
         Agreement.

14.      Product Recall
         --------------

         AstraZeneca  shall have sole  discretion  over  whether  and under what
         circumstances to require the recall of a batch of Product. In the event
         that a recall of a batch of Product  from sale is necessary as a result
         of the  willful  misconduct  or  negligence  of  Inyx,  Inyx  shall  be
         responsible for all costs relating thereto.  In the event that a recall
         is  necessary  for reasons in addition  to the  willful  misconduct  or
         negligence of Inyx, then Inyx and AstraZeneca  shall be responsible for
         a proportionate  share of such costs, to be agreed between the Parties.
         Subject to the above, AstraZeneca shall bear the costs of any recall in
         any other circumstances.

                                       8
<PAGE>

15.      Responsibilities For Scrapped/Wasted Materials
         ----------------------------------------------

15.1     Inyx shall base the planning and purchasing of raw  materials/packaging
         components upon purchase orders issued by AstraZeneca.

15.2     If Inyx initiates any change in raw materials/packaging  components, as
         set out in the QAA  between  the  parties,  Inyx  shall  take all costs
         associated with such change, including for scrapped/wasted materials.

15.3     If AstraZeneca initiates a change in raw materials/packaging components
         or  terminate/withdraw  a Product from the market the Parties  shall in
         good faith plan for the termination in order to minimize Inyx's cost of
         waste.   AstraZeneca  shall  take  such  costs  associated   therewith,
         including for scrapped/wasted  materials, at the maximum six (6) months
         of need of the stock of raw material/packaging components from the date
         of notice of such change or termination/withdraw of Product.

15.4     Products and waste  material  from Inyx's  manufacture  of the Product,
         which carries the AstraZeneca name or logo or a product name or similar
         (below  jointly  referred to as "Waste")  shall be destroyed by Inyx as
         soon as possible  (without  jeopardizing  supply) and such  destruction
         shall be confirmed to  AstraZeneca.  Until  destruction has taken place
         the  Waste  shall  be  stored  and  handled  in  a  manner   preventing
         unauthorized access and possible misuse.

16.      Printed Packaging and Artwork
         -----------------------------

16.1     Inyx shall be  responsible  for the  handling of artwork on the printed
         packaging, in agreement with each Affiliate of AstraZeneca.

16.2     Any change to the  artwork  shall be  initiated  by either  Party via a
         Packaging Administration Form (PAF) or similar and be work processed as
         set out in Exhibit 6, General Work Flow for the Artwork Process.

16.3     The costs  relating to changes in the artwork are  allocated as set out
         in Article 15.

17.      Ownership and Use
         -----------------

17.1     AstraZeneca  is the owner of the  AstraZeneca  Property,  including all
         drawings  (in  paper  or  electronically),   including  any  subsequent
         modifications and improvements, and has full right and title thereto.

17.2     The  AstraZeneca  Property may only be utilized for the sole purpose of
         supply of Products to AstraZeneca or its Affiliates.

17.3     Inyx shall provide  standard  routine  maintenance  of the  AstraZeneca
         Property  and  property  purchased  by Inyx and used in  production  of
         Products,  (if software  such as drawings and other  related  documents
         that are  stating  changes)  at the cost of Inyx as  required to secure
         uninterrupted  Product supply.  Inyx will perform any other maintenance
         or upgrade requested by AstraZeneca at AstraZeneca's expense.

                                       9
<PAGE>

17.4     AstraZeneca  will ensure that all  AstraZeneca  Property is  adequately
         covered by  appropriate  insurance to its full  reinstatement  value in
         case of damages to it outside  the  control of Inyx.  Inyx will  ensure
         that all AstraZeneca  Property and property  purchased by Inyx and used
         in  production  of  Products  is  adequately   covered  by  appropriate
         insurance  to its  replacement  value  to the  extent  not  covered  by
         AstraZeneca's insurance.

17.5     Inyx will ensure that all AstraZeneca  Property owned by AstraZeneca is
         clearly marked as such and shall be tagged with an Inyx' identification
         number and listed accordingly in Inyx' asset register.

17.6     The  condition  of  AstraZeneca  Property  shall be reviewed at regular
         intervals.  In addition,  Inyx shall on an annual  basis in  connection
         with the annual price review  provide  AstraZeneca  with an estimate of
         usage and forecasts for routine refurbishment,  if any, required in the
         following twelve (12) months on AstraZeneca Property.

17.7     In the  case of  termination  of this  Agreement  for any  reason,  the
         Parties shall in good faith  negotiate any  acquisition  by Inyx of any
         AstraZeneca Property.

18.      Legal and Regulatory Requirements
         ---------------------------------

18.1     Inyx shall comply with all relevant and applicable local, national, and
         international  legal  requirements  ("Applicable  Laws")  and any other
         relevant  requirements   applicable  in  respect  of  the  manufacture,
         handling, transport and storage of the Product at all times.

19.      Corporate Responsibility
         ------------------------

19.1     AstraZeneca   does  business  with  parties   conducting  in  a  manner
         consistent   with   AstraZeneca's    policies   concerning   "Corporate
         Responsibility"  (as in effect  from time to time).  AstraZeneca  shall
         provide Inyx with the latest edition of this policy.

19.2     Inyx  represents  and warrants that Inyx will perform this Agreement in
         material   compliance  with  all  applicable   laws  and   regulations,
         including,  without  limitations,  laws  and  regulations  relating  to
         Safety,  Health and Environment  (SHE) relating to the Products and the
         raw materials  used in connection  therewith and relating to fair labor
         practices and unlawful discrimination.

19.3     AstraZeneca and Inyx shall, as soon as practicable upon commencement of
         the services,  meet to discuss the  performance of services and sharing
         of best  practices  in  order  to  find  opportunities  for  continuous
         improvements in Corporate  Responsibility  objectives in the context of
         this Agreement.

20.      Additional Representations and Warranties
         -----------------------------------------

20.1     Inyx  represents  and  warrants,  to  the  best  of its  knowledge,  to
         AstraZeneca that:

         20.1.1   Inyx is the lawful  owner,  lessee or  licensee  of all plant,
                  equipment,   machinery,   Intellectual   Property  Rights  and
                  know-how,  as well as all permissions required, to enable Inyx
                  to perform its obligations under this Agreement;

                                       10
<PAGE>

         20.1.2   the  performance  by Inyx of its  obligations  to  AstraZeneca
                  under this  Agreement  will not breach or be in conflict  with
                  any covenant or  obligation  of Inyx to any third  party,  and
                  will not infringe any rights of any third party;

         20.1.3   Inyx will inform AstraZeneca promptly in writing of any event,
                  which in the reasonable  judgment of Inyx may adversely affect
                  (i) Inyx's  ability to  manufacture  or supply the Products or
                  (ii) the  suitability of the Products for  AstraZeneca's  use;
                  and

         20.1.4   at the time of delivery of each  Product to  AstraZeneca,  (i)
                  such Product will have been manufactured,  handled, stored and
                  transported  in  accordance   with  all  Applicable  Laws  and
                  applicable  regulations  and (ii) such  Product will have been
                  manufactured  in accordance,  and be in  conformity,  with the
                  Product  Requirements and the Quality Assurance  Agreement and
                  will conform with the  certificates  provided  pursuant to the
                  Quality Assurance Agreement.

21.      Force Majeure
         -------------

21.1     Subject to Section  21.3, a Party's  obligations  under this  Agreement
         will  be  suspended  to the  extent  and  for  the  duration  that  its
         performance is delayed,  hindered or prevented by  circumstances  which
         are not within its reasonable control ("Force Majeure").

21.2     For the  purposes  of this  Section,  Force  Majeure  includes  acts or
         restraints of governments or public authorities,  war, revolution, riot
         or civil commotion,  strikes,  lock-outs  (except relating to a Party's
         own employees),  blockage or embargo, explosion, fire, flood or natural
         disaster,  to the  extent  that  any of these  events  are  beyond  the
         reasonable control of the affected Party.

21.3     A Party affected by any event of Force Majeure shall:

         21.3.1   promptly in writing  notify the other  Party,  explaining  the
                  nature,  details and  expected  duration  of such event.  Such
                  Party  shall also  notify the other Party from time to time as
                  to when  the  affected  Party  reasonably  expects  to  resume
                  performance in whole or in part of its obligations  hereunder,
                  and notify the other Party of the cessation of any such event;
                  and

         21.3.2   use its  commercially  best efforts to resume full performance
                  of its obligations  under this Agreement as soon as reasonably
                  practical; and

         21.3.3   pending such resumption,  use its commercially best efforts to
                  facilitate  any  efforts  that  the  other  Party  may make to
                  procure an alternative  method by which its obligations  under
                  this Agreement may be performed.

21.4     If a Party  anticipates that an event of Force Majeure may occur,  such
         Party shall notify the other Party of the nature,  details and expected
         duration of such event.

                                       11
<PAGE>

21.5     If, as a result of Force  Majeure,  Inyx is  unable to  manufacture  or
         supply the full  amount of  Product  ordered  by  AstraZeneca  or which
         AstraZeneca would have ordered but for such circumstances, then:

         21.5.1   AstraZeneca shall purchase the amount of Products Inyx is able
                  to supply,  but at the Price which would have applied had Inyx
                  been  able to  manufacture  and  supply  and  had  AstraZeneca
                  purchased the quantities actually required by AstraZeneca, and
                  the amount  AstraZeneca  would have ordered but for such Force
                  Majeure  shall be taken  into  account  when  calculating  any
                  volume  discount  as if  AstraZeneca  had  purchased  the full
                  amount from Inyx; and

         21.5.2   if such circumstances continue or are forecast to continue for
                  more than  three (3)  months,  Inyx  shall use all  reasonable
                  efforts to offer to AstraZeneca alternative capacity or supply
                  for Product (at prices and on terms to be agreed) which can be
                  operable  within a further  three  (3)  months,  to  standards
                  compliant with the Quality Assurance Agreement; and

         21.5.3   Inyx shall allocate all available capacity of Product produced
                  by Inyx as between  AstraZeneca  and other  customers  of Inyx
                  proportionally  in  accordance  with the amount of Product and
                  other  products  supplied to AstraZeneca  and other  customers
                  during the twelve (12) months prior to such Force Majeure.

21.6     If, as a result of Force Majeure,  AstraZeneca is unable to take or use
         the Product  which has been  ordered,  or which would have been ordered
         but for AstraZeneca's inability to take or use the Product, AstraZeneca
         will only be obliged to purchase such Products under purchase orders it
         has placed for the Product.

21.7     If a Force Majeure prevails for a continuous  period in excess of three
         (3) months,  the Party which is to be notified of such circumstances in
         accordance  with Section  21.3.1 may terminate this Agreement by giving
         written  notice  of  termination  with  immediate  effect  to the Force
         Majeure Party.

22.      Term and Termination
         --------------------

22.1     This Agreement shall be effective during the Term.

22.2     Either Party may terminate this  Agreement  without cause by giving the
         other party twelve (12) months prior written notice,  provided however,
         that such  notice of  termination  may not be given  during the initial
         thirty (30) months of the Term.

22.3     This  Agreement will  automatically  terminate in case the Parties have
         not executed a formal QAA by the latest on the 1 September 2004, unless
         otherwise  agreed in Such QAA shall be  appended to this  Agreement  as
         Exhibit 4.

22.4     Notwithstanding  Section  22.2,  if the tech  transfer,  validation  of
         commercial  batches or QA  inspections  by  regulatory  authorities  in
         connection  therewith  are delayed  more than sixty (60) days or do not
         pass  successfully  in  AstraZeneca's   qualified  opinion,  then  this
         Agreement  may be  terminated  immediately  upon  written  notice  from
         AstraZeneca.

                                       12
<PAGE>

22.5     Termination by Either Party. In addition to any other provision of this
         Agreement expressly  providing for termination of this Agreement,  this
         Agreement may be terminated  immediately by either Party upon notice to
         the other Party:

         22.5.1   in the event of a breach of this Agreement by the other Party,
                  where such breach is capable of cure and such  breach  remains
                  uncured and has not commenced to be cured for twenty (20) days
                  after  notice of such breach and the breach is still not cured
                  within a reasonable  time - such  reasonable time shall be set
                  in relation to the  particular  circumstances  of the relevant
                  breach - but in no event will the reasonable  time last longer
                  than  hundred  and  eighty  (180)  days  after  notice of such
                  breach;

         22.5.2   in the event of a  material  breach of this  Agreement  by the
                  other Party where such breach is not capable of cure;

         22.5.3   if the other Party shall file in any court or agency, pursuant
                  to any  statute  or  regulation  of any  state or  country,  a
                  petition in bankruptcy or insolvency or for  reorganization or
                  for an the  appointment of a receiver or trustee of such other
                  Party or of its  assets,  or if the  other  Party  proposes  a
                  written agreement of composition or extension of its debts, or
                  if the  other  Party  shall  be  served  with  an  involuntary
                  petition against it, filed in any insolvency proceeding, or if
                  the other Party shall propose or be a party to any dissolution
                  or liquidation, or if the other Party shall make an assignment
                  for the benefit of its creditors;

         22.5.4   if any  encumbrancer  takes possession of any material part of
                  the assets of the other Party;

         22.5.5   if any distress,  execution or other such process is levied or
                  enforced  upon or against  any of the  material  assets of the
                  other Party;

         22.5.6   if the other Party  ceases or  threatens  to cease to carry on
                  the whole or  substantially  the whole of its business or that
                  part of its business to which this Agreement relates.

22.6     Notwithstanding Section 22.2, if AstraZeneca, including its Affiliates,
         decides  not to  launch  the  Product  for any  reason  or  ceases  the
         marketing and sale of the Product for any reason, this Agreement may be
         terminated immediately upon written notice from AstraZeneca. In case of
         such  termination,  AstraZeneca  will  compensate  Inyx  by  paying  as
         follows:

         (a)      the Price for any stock of the  Product not yet  released  and
                  delivered  to  AstraZeneca  in  volumes  which are  ordered by
                  AstraZeneca and confirmed by Inyx to AstraZeneca.

         (b)      the direct cost for the  volumes of Product in progress  which
                  are  ordered  by   AstraZeneca   and   confirmed  by  Inyx  to
                  AstraZeneca.

                                       13
<PAGE>

         (c)      Inyx's direct costs for raw  materials and other  materials in
                  Inyx's stock at the date of such termination and purchased for
                  the use in the  manufacture of the Product.  The  compensation
                  under this sub-paragraph (c) is given provided that:

                  (i)      the volumes of raw materials and other  materials are
                           within AstraZeneca's latest Forecast and for a period
                           not  exceeding  three  (3)  months  from  the date of
                           AstraZeneca's notice;

                  (ii)     the  raw   materials  and  other   materials   cannot
                           reasonably be used for other purposes by Inyx; and

                  (iii)    AstraZeneca is entitled to collect such raw materials
                           and other materials for its own use or sale,  without
                           additional charge.

22.7     AstraZeneca may terminate this Agreement immediately upon giving notice
         to Inyx in the event of a Change of Control of Inyx.

22.8     Without  prejudice to any other  rights or remedies  which either Party
         may have, upon the termination of this Agreement each Party shall:

         22.8.1   immediately  pay to the other Party all undisputed  sums which
                  at the date of  termination  are due and  payable to the other
                  Party under this Agreement; and

         22.8.2   immediately  cease all use of any property of the other Party,
                  including any Intellectual  Property Rights of the other Party
                  under this Agreement; and

         22.8.3   within twenty eight (28) days of such termination,  at its own
                  expense,  return to the other Party any  property of the other
                  Party in its  possession,  custody or control,  including  all
                  Confidential  Information of that Party and copies of it under
                  this Agreement; provided, however, that a Party may retain one
                  (1) copy of the  other  Party's  Confidential  Information  in
                  order to ensure  compliance  with its obligations set forth in
                  this Agreement; and

         22.8.4   at  AstraZeneca's  request  and cost,  assist  AstraZeneca  in
                  finding an  alternative  supplier  and  supply all  reasonable
                  assistance   and  support  in   transferring   the  Supply  of
                  Product(s) to such alternative supplier.

22.9     Articles  1, 2, 14,  25 (as set out in 25),  26, 27 (as set out in 27),
         29, 34 and 35, and this Section 22.9 will survive expiry or termination
         of this Agreement, howsoever the same occurs.

23.      Tech Transfer to AstraZeneca or a Second Supplier
         -------------------------------------------------

         Upon AstraZeneca's request, Inyx shall provide all necessary and useful
         technology  transfer  documentation  and know-how for the manufacturing
         process, testing, release and delivery of the Product to AstraZeneca or
         such second supplier as AstraZeneca designates at cost at AstraZeneca's
         expense.

                                       14
<PAGE>

24.      Most Favored Customer
         ---------------------

Notwithstanding anything herein to the contrary, if, at any time during the Term
the Price for the Product  exceeds the lowest  delivery  price at which Inyx (or
any of its Affiliates)  offers equal  quantities of a similar product on similar
terms and comparable quality to any of its other customers,  Inyx shall promptly
notify  AstraZeneca  of that fact and the Price for such Product will be reduced
for all deliveries of the Product after the date of Inyx's notice of that lowest
delivery price, for so long as it continues to apply.

25.      Confidentiality
         ---------------

25.1     Except  as  otherwise  provided  in this  Agreement,  any  Confidential
         Information which is disclosed by or on behalf of a Disclosing Party to
         the Receiving Party will remain the property of the Disclosing Party.

25.2     The Receiving Party undertakes:

         25.2.1   to use the Confidential Information solely and exclusively for
                  the purposes of this  Agreement  (or such other  purpose as is
                  agreed  in  writing   between  the  Parties  at  the  time  of
                  disclosure),  and not to use the Confidential  Information for
                  any  other  purpose  whatsoever,  including  the  development,
                  manufacture,  marketing,  sale or  licensing of any process or
                  product or any other commercial purpose anywhere in the world,
                  unless  the  Parties   enter  into  an  agreement   specifying
                  otherwise; and

         25.2.2   to   maintain   the   confidentiality   of  the   Confidential
                  Information  and not to disclose it directly or  indirectly to
                  any other company,  organization,  individual or third Person,
                  except as permitted by Section 25.3.

25.3     Notwithstanding   Section  25.2,  the  Receiving   Party  may  disclose
         Confidential  Information  to any of its  Affiliates,  and  its and its
         Affiliate's directors,  employees and professional advisers who need to
         know the  Confidential  Information  in order to fulfill the purpose of
         this  Agreement,  provided that the Receiving Party procures that prior
         to such disclosure,  each such Person to whom Confidential  Information
         is to be disclosed is made aware of the  obligations  contained in this
         Agreement,  and  adheres  to these  terms as if it were a party to this
         Agreement.

25.4     Nothing in Section 25.2 will preclude  disclosure  of any  Confidential
         Information  required  by  any  governmental,   quasi-governmental   or
         regulatory  agency or authority or court  entitled by law to disclosure
         of the  same,  or which is  required  by law or the  requirements  of a
         national  securities  exchange or another similar regulatory body to be
         disclosed,  provided that the  Receiving  Party  promptly  notifies the
         Disclosing Party when such requirement to disclose has arisen to enable
         the Disclosing Party to seek an appropriate  protective  order, to make
         known to the relevant agency,  authority,  court or securities exchange
         the proprietary nature of the Confidential Information, and to make any
         applicable  claim of  confidentiality.  The  Receiving  Party agrees to
         co-operate in any action which the Disclosing Party may decide to take.
         If the  Receiving  Party is required to make a disclosure in accordance
         with this clause, it will only make a disclosure to the extent to which
         it is obliged.

                                       15
<PAGE>

25.5     The  provisions  of  Section  25.2 will not  apply to any  Confidential
         Information   which  the  Receiving  Party  can  demonstrate,   to  the
         reasonable satisfaction of the Disclosing Party:

         25.5.1   was already in the possession of the Receiving Party or any of
                  its  Affiliates  and at the  Receiving  Party's  or any of its
                  Affiliates'  free use and  disposal  or in the  public  domain
                  (through in each case no fault of the  Receiving  Party or any
                  of its  Affiliates  or no  breach  of  this  Agreement  by the
                  Receiving  Party) prior to its  disclosure  by the  Disclosing
                  Party under this Agreement; or

         25.5.2   is purchased or otherwise  legally  acquired by the  Receiving
                  Party or any of its Affiliates at any time from a third Person
                  having and the right to disclose it; or

         25.5.3   comes into the public domain, otherwise than through the fault
                  of the Receiving Party or any of its Affiliates; or

         25.5.4   is  independently  generated by the Receiving  Party or any of
                  its  Affiliates  without  any  recourse  or  reference  to the
                  Confidential Information.

25.6     The obligations of each Party in this Section will survive for a period
         of ten (10) years after the date of expiration or  termination  of this
         Agreement.

26.      Improvements
         ------------

26.1     Inyx shall promptly disclose to AstraZeneca details of all Improvements
         which Inyx  conceives,  reduces to  practice,  develops,  discovers  or
         otherwise  makes  during  the Term  relating  to the  Product,  and the
         manufacture and supply thereof.

26.2     AstraZeneca  will have  exclusive  ownership  of all  right,  title and
         interest in and to any such  Improvements  relating to the Products and
         Inyx shall and does  hereby  assign to  AstraZeneca  any and all right,
         title or interest of Inyx in or to such Improvements.

26.3     AstraZeneca  grants  Inyx  a  non-exclusive,   perpetual,   irrevocable
         worldwide  fully paid up license to any  Improvements  relating  to the
         manufacture process.

26.4     Inyx shall, upon  AstraZeneca's  request and at AstraZeneca's  expense,
         execute all such  documents  and do all such things as may be necessary
         to vest in  AstraZeneca  the entire  right,  title and interest to such
         Improvements.

26.5     AstraZeneca at all times shall own the AstraZeneca Information. Inyx at
         all times shall own the Inyx Information.

27.      Insurance
         ---------

         Inyx shall maintain during the Term and for three (3) years  thereafter
         insurance coverage of the types and in the amounts typically carried by
         companies  in  the  pharmaceutical   business.  Inyx  will  exhibit  to
         AstraZeneca upon written request  certificates of insurance  evidencing
         its insurance coverage and limits.

                                       16
<PAGE>

28.      Use of Name
         -----------

28.1     Except as  provided  under  Section  28.2,  neither  Party may make any
         announcement  about the  transactions  contemplated  by this  Agreement
         without the prior written consent of the other Party.

28.2     Each Party  shall not  mention  or  otherwise  use the name,  insignia,
         symbol,  trademark,  trade name or  logotype  of the other Party or its
         Affiliates in any publication,  press release,  promotional material or
         other form of publicity  without the prior written consent of the other
         Party in each  instance.  The  restrictions  imposed by this Article 28
         shall not prohibit either Party from making any disclosure  identifying
         the other Party that is required by applicable  law, rule or regulation
         or the  requirements  of a  national  securities  exchange  or  another
         similar  regulatory  body,  provided that any such disclosure  shall be
         governed by Article 25.

29.      Notices
         -------

         Any notice, request or other communication  permitted or required under
         this Agreement  shall be in writing,  shall refer  specifically to this
         Agreement  and shall be deemed given only if hand  delivered or sent by
         an  internationally   recognized  overnight  delivery  service,   costs
         prepaid,  or by facsimile (with transmission  confirmed),  addressed to
         the Parties at their  respective  addresses first set forth above or to
         such other  address as the Party to whom notice is to be given may have
         provided to the other Party in  accordance  with this  Section 29. Such
         notice,  shall be deemed to have been given as of the date delivered by
         hand or transmitted by facsimile (with transmission  confirmed),  or on
         the second  business day (at the place of delivery)  after deposit with
         an internationally  recognized overnight delivery service, whichever is
         the earlier.  Any notice delivered by facsimile shall be confirmed by a
         hard copy delivered as soon as practicable thereafter.  This Section is
         not intended to govern the day-to-day business communications necessary
         between the Parties in performing their  obligations under the terms of
         this Agreement.

30.      Relationship of the Parties
         ---------------------------

30.1     The  status  of a  Party  under  this  Agreement  shall  be  that of an
         independent  contractor.  Nothing  contained in this Agreement shall be
         construed  as  creating  a   partnership,   joint   venture  or  agency
         relationship between the Parties.

31.      Assignment
         ----------

31.1     This  Agreement may not be assigned by either Party in whole or in part
         without the prior  written  consent of the other Party,  which  consent
         shall not be unreasonably  withheld,  except that  AstraZeneca  without
         such consent may assign this  Agreement and its rights and  obligations
         hereunder  to any of  its  Affiliates  or  any  successor  in  interest
         (whether by merger, acquisition, asset purchase or otherwise) to all or
         substantially all of the business to which this Agreement relates.

31.2     AstraZeneca  shall  always  have the right to perform any or all of its
         obligations  and exercise any or all of its rights under this Agreement
         through any of its Affiliates.

                                       17
<PAGE>

32.      Expenses
         --------

         Except as otherwise  expressly  provided in this Agreement,  each Party
         shall pay the fees and expenses of its respective lawyers and all other
         expenses  and  costs   incurred  by  such  Party   incidental   to  the
         negotiation, preparation, execution and delivery of this Agreement.

33.      Waiver and Non-Exclusion of Remedies
         ------------------------------------

33.1     A Party's  failure to  enforce,  at any time or for any period of time,
         any  provision  of this  Agreement,  or to exercise any right or remedy
         shall not  constitute  a waiver of that  provision,  right or remedy or
         prevent  such  Party  from  enforcing  any or all  provisions  of  this
         Agreement and  exercising  any rights or remedies.  To be effective any
         waiver must be in writing.  Subject to Section 12.4 and the requirement
         that the  Parties  submit to binding  arbitration  in  accordance  with
         Section 35, all rights and remedies are  cumulative  and do not exclude
         any other right or remedy provided by law or otherwise available.

33.2     The payment of the invoices by AstraZeneca  under Section 10.2 will not
         operate  as any  waiver  by  AstraZeneca  any  right,  power or  remedy
         provided by law or under this Agreement.

34.      Severability
         ------------

         If any  provision of this  Agreement is held to be invalid,  illegal or
         unenforceable, in any respect, then, to the fullest extent permitted by
         applicable  law and if the rights or  obligations of any Party will not
         be materially and adversely affected:  (a) such provision will be given
         no effect by the Parties and shall not form part of this Agreement; (b)
         all other  provisions of this Agreement  shall remain in full force and
         effect and (c) the Parties  will use their best  efforts to negotiate a
         provision in  replacement  of the provision  held  invalid,  illegal or
         unenforceable  that is consistent with applicable law and achieves,  as
         nearly as  possible,  the original  intention  of the  Parties.  To the
         fullest  extent  permitted by  applicable  law,  the Parties  waive any
         provision  of law that would  render any  provision  in this  Agreement
         invalid, illegal or unenforceable in any respect.

35.      Governing Law and Disputes
         --------------------------

35.1     The interpretation and construction of this Agreement shall be governed
         by the laws of Sweden  excluding any conflicts or choice of law rule or
         principle that might otherwise refer  construction or interpretation of
         this Agreement to the substantive law of another jurisdiction.

35.2     Except as set forth in Section  12.4,  any  dispute  arising  out of or
         relating to this Agreement  shall be settled by binding  arbitration in
         accordance   with  the  Stockholm   Chamber  of  Commerce's   rules  of
         arbitration. The number of arbitrators shall be three (3), of whom each
         Party shall  appoint one (1). The two  arbitrators  so  appointed  will
         select the third and final  arbitrator.  The place of arbitration shall
         be  Stockholm  in  Sweden.   The  language  used  in  the   arbitration
         proceedings shall be English.  The proceedings,  including any outcome,
         shall be confidential.  Nothing in this Section will preclude any Party
         from seeking  interim or  provisional  relief from a court of competent
         jurisdiction,  including a  temporary  restraining  order,  preliminary

                                       18
<PAGE>

         injunction  or other  interim  equitable  relief,  concerning a dispute
         either prior to or during any  arbitration  if necessary to protect the
         interests  of such Party or to  preserve  the status  quo  pending  the
         arbitration proceeding.

35.3     The Parties agree to use best  commercial  efforts to mutually  resolve
         any and al outstanding disputes or issues that may arise as a result of
         this Agreement.

36.      Counterparts
         ------------

         This Agreement is executed in two (2) counterparts, each of which shall
         be deemed an original and all of which taken  together  shall be deemed
         to constitute one and the same instrument.

37.      Execution
         ---------

THIS AGREEMENT IS EXECUTED by the authorized  representatives  of the Parties as
of the date first written above.

SIGNED for and on behalf of                   SIGNED for and on behalf of

AstraZeneca AB (publ)                         Inyx Pharma Ltd

s/s K. Johannsson, H. Sharte                  s/s Steven Handley
----------------------------------            ----------------------------------
Signature                                     Signature

Name:   K. Johansson, H. Sharte               Name:    Steven Handley
Title:  VP Supply/CFO, LPS                    Title:   President and Director

                                       19
<PAGE>

                                    Exhibit 1
                                    ---------

                     PRODUCT, PRODUCT REQUIREMENTS AND PRICE

1.       Product
         -------

         Pulmicort HFA pMDl

2.       Product Requirements
         --------------------

         Art. no..specified in the QAA.

         Art. no..specified in the QAA.

3.       Price
         -----
         Product 100g/ dose -                   120 doses -GBP One  thousand one
                                                hundred  thirty  seven  809/1000
                                                ((pound)1,137.809)  per thousand
                                                (1,000) units for.

         Product 200g/ dose - 120 doses -       GBP  One  thousand  two  hundred
                                                eighty        eight       9/1000
                                                ((pound)1,288.009)  per thousand
                                                (1,000) units for.

         Product l00g/ dose - 120 doses without secondary packaging and actuator
         packaged product) -                    (bulk  drug  GBP  Eight  hundred
                                                ninety      eight       809/1000
                                                ((pound)898.809)   per  thousand
                                                (1,000) units.

         Product 200g/ dose - 120 doses without secondary packaging and actuator
         packaged product) -                    (bulk  drug  GBP  One   thousand
                                                forty       nine        009/1000
                                                ((pound)1,049.009)  per thousand
                                                (1,000) units.

3.1      The Price  includes  the  components  specified  in the cost break down
         below:

------------------------------- --------------- ---------------- ---------------
                                                     PRICE            PRICE
                                                 ((pound))/1000   ((pound))/1000
  Characteristic & ref. No.       Supplier           Product          Product
------------------------------- --------------- ---------------- ---------------
                                                  100g/ dose         200g/ dose
                                                  - 120 doses        - 120 doses
------------------------------- --------------- ---------------- ---------------
Filling, Function Testing and   Inyx                302.000             302.00
primary packaging of Product

------------------------------- --------------- ---------------- ---------------
Budesonide micronized           AstraZeneca         150.200             300.400

------------------------------- --------------- ---------------- ---------------
LIGA Mg-sterate, MF-2-V         Tracomme AG           0.009               0.009

------------------------------- --------------- ---------------- ---------------

                                       1-1

<PAGE>

------------------------------- --------------- ---------------- ---------------
HFA 134a, HFA Zephex 134a       Ineos Limited        90.000              90.000

------------------------------- --------------- ---------------- ---------------
Cans:  12 ml, AL, C1148P,       Presspart            36.600              36.600
slimline plain base

------------------------------- --------------- ---------------- ---------------
Valves:  DF 31/50 RCU,          Inyx Dispray        320.000             320.000
10006319

------------------------------- --------------- ---------------- ---------------
TOTAL PRICE BULK DRUG PRODUCT                       898.809           1,049.009
-----------------------------

------------------------------- --------------- ---------------- ---------------
Secondary Packaging:            Inyx                 88.000              88.000

------------------------------- --------------- ---------------- ---------------
Carton and Leaflet:             Inyx' Supplier       32.000              32.000
                                as approved by
                                AstraZeneca

------------------------------- --------------- ---------------- ---------------
Actuators:  120D AstraZeneca    Betts UK            119.000             119.000
Assy 0.6 mm orif/3.2 stem
FP1157

------------------------------- --------------- ---------------- ---------------
TOTAL PRICE PRODUCT                               1,137.809           1,288.009
-------------------

------------------------------- --------------- ---------------- ---------------

4.       Minimum remaining shelf life
         ----------------------------

         Inyx  shall  only  deliver  Products  with a  remaining  shelf  life of
         eighteen (18) months at the time of delivery.

5.       Invoice address
         ---------------

         AstraZeneca AB

         AstraZeneca Sweden Operations

         Accounts Payable B416

         151 85 Sodertalje

         Sweden

6.       Fixed Price Term
         ----------------

         The  Prices  shall be fixed  and not  subject  to  variation  until and
         including 31 December  2005.  Thereafter  the Prices shall be fixed and
         not  subject to  variation  for one (1) year terms  beginning 1 January
         2006.

                                      1-2

<PAGE>

7.       Price Review Date
         -----------------

         Either party may initiate the review of the price at the earliest three
         (3) months prior to the expiry of the Fixed Price Term.

8.       Price Review Parameters
         -----------------------

         As the basis for the review of the Price,  the Parties  shall take into
         account labor cost, efficiency improvements,  material costs, inflation
         rate in the UK and other costs, all according to the indices set out in
         the Price  Revision  Formula and the continuous  improvements  achieved
         under Article 11.

9.       Price Review Formula
         --------------------

                     L1
                     --
         P = Po (a x L2 + b x M1 + c)
             --      --       --
             100    Prod      M2

         where

         P =      final price for invoicing

         Po=      price according to Supply Agreement

         Ll =     index  for  average  earnings  (excluding  bonuses)  based  on
                  average     from     preceding     year    prior     delivery.
                  (www.statistics.gov.uk/cci/nugget.asp?id=10).

         L2 =     index for  average  earnings  (excluding  bonuses) of the base
                  month. Base month as defined below.

         M1 =     index for materials based on average from preceding year prior
                  delivery.    Index   for   Chemicals,    calculated   out   of
                  Importprisindex   (IMPI),   1990=100   after   product   group
                  Prod-SNI97

         M2 =     index for materials for the base month.  Base month as defined
                  below.

         Prod =   productivity improvement index for labor           Prod = 1,05

         a =      percentage proportion of wages                      a = 45%

         b =      percentage proportion of materials                  b = 45%

         c =      percentage proportion of other costs, not index reg. C = 10%

         Base month is defined as the Month of June 2004.

         Example of how the Price Review Formula is applied:
         ---------------------------------------------------

         Assume wages index goes up by      3%

                                      1-3
<PAGE>

         Assume material costs go up by     4%

         Non intended costs                 10% (fixed)

                                                  --                         --
                                                 |                             |
         Price            =       1,137.809      | 45% x 1.03 + 45% x 1.04 + 10|
                                  ---------      |       ---                   |
                                     100         |      1.05                   |
                                                 |                             |
                                                  --                         --

                          =       1,137.809    (|44.14285 + 46,8 + 10)
                                  ---------
                                     100

         New Price        =        (pound)1,148.537

10.      Payment details
         ---------------

         Barclays Bank PLC
         Barclays Business Centre
         PO Box 100, Leeds LS 1 IPA
         Account name Inyx Pharma LTD,
         Account number: 00402087
         Sort code  20-48-46

                                      1-4
<PAGE>

                                    Exhibit 2

                              LOGISTIC ARRANGEMENTS

Delivery:

The Products shall be delivered Ex Works (Incoterms 2000).

Means of Transport:

By truck.

Transport Requirements:

Products shall always be  transported  in rigid box trailers  under  temperature
control.  The  temperature  shall be  between  +2-+25  degrees  Celsius,  unless
AstraZeneca provides Inyx with specific written instructions.
Temperature monitor should be used during transportation i.e. from loading on to
truck  until  and  including   receipt  at  AstraZeneca's   central   warehouse.
AstraZeneca will provide monitors or other temperature trace recorders.

Carrier:

     o    The goods shall be packed on EUR-pallet (1200 x 800 mm).

     o    Maximum height for the loading incl. the pallet is 1150 mm.

     o    The loading shall be fixed with a sheet on the top and shrink  wrapped
          or stretch banded.

     o    No overhang outside the EUR-pallets external dimension.

     o    The goods shall be marked on both shorter sides.

     o    Part box / Sample box should be clearly marked.

     o    Only one product and batch on each pallet.

     o    The pallet shall be dry, clean and undamaged.

Marking:

The carrier shall be marked with a label on both sides of the load.
The following information shall be stated on the label:
- Inyx's name
- AstraZeneca's article number
- AstraZeneca's purchasing order reference
- Lot no.

                                      2-1
<PAGE>

- Quantity (sales unit)
- Pallet/package no. referring to the packing list/delivery note
- Market country

Each shipper (carton) shall be marked with its content:
- AstraZeneca article No.
- Lot no.
- Expiry date
- Name of the Product
- No. of units/shipper
- Market country

Forwarding Agent:

Delivery address:

According to Purchase Order by AstraZeneca.

Exchange of Documents:

Documents shall be sent to Distribution & Nordic Supply Point

Forecast/confirmation
Purchase order/confirmation
Delivery plan/confirmation
Deviation report when necessary
Shipping advice

Shipping advice:

The shipping  advice shall be sent by mail or fax to  AstraZeneca  at the latest
the same day as the Products are shipped from lynx. The advice shall contain the
same information regarding the actual shipment as the delivery note.

Delivery note/Packing list:

Delivery  note/Packing list shall always be included in the delivery and clearly
marked.

Following information shall be stated on the note/list:
- AstraZeneca purchase order reference
- AstraZeneca article No.
- Lot no.
- Manufacturing year/month - Expiry date
- Each pallet no and number of units per pallet
- Total number of units (sales unit)

                                      2-2

<PAGE>

With Products:

- Delivery note/Packing list
- Forwarding documents
- Certificate of Analysis (except if the Products are managed with QP release)

By Separate Mail:

Invoice

                                      2-3
<PAGE>
<TABLE>
<CAPTION>

                                    Exhibit 3

                                 CONTACT PERSONS

Contact  persons  in matters  relating  to the  supply  and  manufacture  of the
Products are the persons  indicated below, or such other persons as subsequently
notified by one party to another:

another:

--------- ----------------- ------------------ ----------------------------------- ------------------
Company   Activity          Contact Name       E-mail                              Telephone
                                                                                   Number
--------- ----------------- ------------------ ----------------------------------- ------------------
<S>       <C>               <C>                <C>                                 <C>
Inyx      Commercial        Uli Bartke         Uli.bartke@inyx-pharma.co.uk        +44 1928 532 226

--------- ----------------- ------------------ ----------------------------------- ------------------
Inyx      Consecutive       Christine          christine.carmichael@inyx-          +44 1928 532 238
                            Carmichael         pharma.co.uk

--------- ----------------- ------------------ ----------------------------------- ------------------
Inyx      Technical         John Hamer         John.hamer@inyx-pharma.co.uk        +44 1928 532 219
          Matters/
          Packaging/
          Material/Artwork

--------- ----------------- ------------------ ----------------------------------- ------------------
Inyx      Regulatory        Colin Hunter       Colin.Hunter@inyx-pharma.co.uk      +44 1928 532 265

--------- ----------------- ------------------ ----------------------------------- ------------------
Inyx      Change Control/   Anastasia Loftus   Anastasia.Luftus@inyx-pharma.co.uk  +44 1928 502 204
          Product
          Maintenance

--------- ----------------- ------------------ ----------------------------------- ------------------
--------- ----------------- ------------------ ----------------------------------- ------------------
AZ        Commercial        Madeleine Rudlid   madeleine.rudlid@astrazeneca.com    +46 8 553 273 50

--------- ----------------- ------------------ ----------------------------------- ------------------
AZ        Consecutive
--------- ----------------- ------------------ ----------------------------------- ------------------
AZ        Technical         Martin Persson     Martin.EK.Persson@astrazeneca.com   +46 8 553 275 58
          Matters/
          Packaging/
          Material/Artwork

--------- ----------------- ------------------ ----------------------------------- ------------------
AZ        Regulatory        Maria Nystrom

--------- ----------------- ------------------ ----------------------------------- ------------------
AZ        Change Control/   Ylva               Ylva.Hezekielsson@astrazeneca.com   +46 8 553 265 98
          Product           Hezekielsson
          Maintenance

--------- ----------------- ------------------ ----------------------------------- -------------------
</TABLE>

                                      3-1
<PAGE>

                                    Exhibit 4

                           QUALITY ASSURANCE AGREEMENT

                to be appended by the latest on I September 2004

                                      4-1

<PAGE>
                                    Exhibit 5

                              AstraZeneca Property

The following list details the assets owned by  AstraZeneca at Inyx'  facilities
for use in the supply of the Products to AstraZeneca all procured year 2004:

DH Industries

     o    Double diaphragm pump

     o    Change parts for filling machine

     o    Change Parts for can sorting machine

     o    Propellant metering system

     o    Suspension flow monitoring system

Kells

     o    Stainless Steel Vessel and Weighing System

Innerflow Engineering

Fixed product supply and return lines dedicated to the AstraZeneca process

Frymakoruma

     o    High shear mixer, which will be integrated with the Kells'vessel

Others (estimate - includes)

     o    Dedicated dispensing equipment for active and magnesium stearate

                                      5-1
<PAGE>

                                   Exhibit 6
                                   ---------

                    GENERAL WORK FLOW FOR THE ARTWORK PROCESS

---------------------                -------------------------------------
AstraZeneca           <---------                  AstraZeneca
Distribution Services              / /        Marketing Company
---------------------             / /-------------------------------------
                                 / /                 |
---------------------------     / /                  |
For  new  products/packs:      / /  -------------------------------------
AZ MC provides                / /                Supplier
Distribution  Services with  / /               PAF + templates
a PAF for information.      / /     -------------------------------------
---------------------------         AstraZeneca Marketing Company -
                                    Create artwork and regulatory
                                    approval by concerned authorities
                                    - Provide regulatory approved artwork
                                    (electronic and paper copy) +
                                    PAF to supplier
                                    -------------------------------------
                                                     |
                                                     |
                                    -------------------------------------
                                                 Supplier
                                              Approved artwork
                                    -------------------------------------
                                                     |
                                                     |
                                    --------------------------------------
                                             Supplier of printed
                                             packaging material
                                              Printed packaging
                                                  material
                                    --------------------------------------
                                                     |
                                                     |
                                    --------------------------------------
                                                 Supplier
                                    - Release printed packaging
---------------------               material for production
AstraZeneca           <---------    - Distribute printed samples of
Marketing Company                   packaging material to AstraZeneca
---------------------               Marketing Company for
                                    information
                                    ---------------------------------------

                                      6-1Exhibit 4.2(e)

April 13, 2004

Dr. Anil Jain
APA Optics, Inc.
2950 NE 84th Lane
Blaine, MN 55449

Dear Dr. Jain,

The Aberdeen Development Corporation and APA Optics, Inc. acknowledge and agree
to the following terms and conditions regarding the outstanding loans between
the two parties:

     -    Aberdeen Development Corporation acknowledges receipt of $89,305.00
          from APA Optics, Inc. to ADC's Wells Fargo bank account
     -    Aberdeen Development Corporation agrees to the release of the UCC
          Filing in the State of Minnesota #1859487 dated June 24, 1996 on the
          equipment located in Blaine, Minnesota which was renewed August 20,
          2001 ( UCC Filing #20013130900028)
     -    Aberdeen Development Corporation will retain the UCC Filing in the
          State of South Dakota #20013130900028 dated November 9, 2001 on the
          equipment located in Aberdeen, SD
     -    APA Optics, Inc. will pay the Aberdeen Development Corporation
          $140,000 payable in seven equal payments of $20,000 starting June 30,
          2004
     -    The interest rate on the loan will remain at 0% interest
     -    All other terms and conditions of the loan will remain in affect.

The above is correct and accurate and we consent to these terms and conditions.

APA Optics, Inc.                        Aberdeen Development Corporation

By:                                     By:
     -----------------------------           -----------------------------
     Dr. Anil K. Jain                        Larry Frost
     Its:  Chairman and President            Its:  President

                                       By:
                                            ------------------------------
                                            James C. Barringer
                                            Its:  Executive Vice-President

<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]